Aurobindo Pharma Q2FY27 Revenue Surges 23.9% to ₹10,263 Cr; EBITDA Up 28.5%
Aurobindo Pharma reported record Q2FY27 revenue of ₹10,263 crore, up 23.9% YoY. EBITDA rose 28.5% to ₹2,156 crore, and Net Profit increased 32.5% to ₹1,124 crore. The company launched 10 US products and completed the Lannett acquisition. Net cash flow was US$ 146 million.
Record financial results, successful strategic acquisitions, and significant product launches have a substantial positive impact on the company's market position, investor confidence, and future growth prospects.
The company reported record-breaking quarterly revenue and EBITDA, significant year-on-year growth across key financial metrics, successful product launches, and strategic acquisitions, indicating strong financial health and operational performance.
Aurobindo Pharma Limited announced its unaudited financial results for the second quarter and half year ended September 30, 2026. The company reported its highest-ever quarterly revenue of ₹10,263 crore, marking a significant 23.9% year-on-year growth. This robust performance was driven by strong contributions across all business segments.
The company's EBITDA also reached a record high of ₹2,156 crore, an increase of 28.5% year-on-year, with an improved EBITDA margin of 21.0%. Net Profit for the quarter stood at ₹1,124 crore, up 32.5% compared to the same period last year. The PBT before tax was ₹1,691 crore, a 32.7% increase year-on-year.
Key business highlights for Q2FY27 include a Net Capex of US$ 89 million primarily for capability enhancements and new business developments. The company launched 10 products in the US market, including gAdvair and ADQUEYTM, its first NCE. Aurobindo Pharma also generated a net cash flow of US$ 146 million during the quarter, maintaining a strong net cash position of approximately US$ 189 million as of September 30, 2026. The successful acquisition of Lannett further strengthened its US presence and expanded capabilities in complex and controlled substances.
Geographically, the USA business grew by 25.2% year-on-year to ₹4,555 crore, and Europe saw a 27.5% increase to ₹3,161 crore. Growth Markets contributed ₹1,026 crore, up 16.3% year-on-year, while ARV business grew by 10.2% to ₹359 crore. The API business reported revenues of ₹1,162 crore, a 20.9% increase year-on-year.
In its Biosimilars and Biologics Contract Manufacturing update, Aurobindo Pharma highlighted progress in its pipeline and capacity expansions. The company is on track for a 2027 target completion for its AUROVACCINES MERGER, which will add microbial and mammalian drug substance capacity. Clinical studies for subcutaneous trastuzumab are set to begin in December 2026, with biosimilar pertuzumab development complete and progressing to the clinic in Q12027. Regulatory progress includes EMA filings for Omalizumab and ongoing CHMP reviews for Denosumab biosimilars. The company also secured marketing authorization in India for Bevqolva (bevacizumab).
The company's US ANDA filings snapshot as of September 30, 2026, shows 900 total filings, with 747 approved and 35 awaiting final approval in Unit-wise ANDA Filings.
What to do with a filing like this
Aurobindo Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aurobindo Pharma Limited. Read the original for the full detail.